Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling?
- PMID: 21859557
- PMCID: PMC3561586
- DOI: 10.1016/j.clcc.2011.03.001
Prognostic and predictive markers in stage II colon cancer: is there a role for gene expression profiling?
Abstract
Conventional clinical and pathologic risk factors in stage II colon cancer provide limited prognostic information and do not predict response to adjuvant 5-fluorouracil-based chemotherapy. New prognostic and predictive biomarkers are needed to identify patients with highest recurrence risk who will receive the greatest absolute risk reduction from adjuvant chemotherapy. We review below the evidence for conventional risk factors in patients with node-negative colon cancer, followed by a discussion of promising new molecular and genetic markers in this malignancy. Gene expression profiling is an emerging tool with both prognostic and predictive potential in oncology. For patients with stage II colon cancer, the Oncotype DX Colon Cancer test is now commercially available as a prognostic marker, and the ColoPrint assay is expected to be released later this year. Current evidence for both of these assays is described below, concluding with a discussion of potential future directions for gene expression profiling in colon cancer risk stratification and treatment decision making.
Copyright © 2011. Published by Elsevier Inc.
Figures
Similar articles
-
Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.Ont Health Technol Assess Ser. 2010;10(23):1-57. Epub 2010 Dec 1. Ont Health Technol Assess Ser. 2010. PMID: 23074401 Free PMC article.
-
Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.JAMA Oncol. 2016 Jan;2(1):37-45. doi: 10.1001/jamaoncol.2015.3413. JAMA Oncol. 2016. PMID: 26502222
-
Evolving role of gene expression signatures as biomarkers in early-stage colon cancer.J Gastrointest Cancer. 2014 Dec;45(4):399-404. doi: 10.1007/s12029-014-9634-7. J Gastrointest Cancer. 2014. PMID: 24989938 Review.
-
Genomic classifier ColoPrint predicts recurrence in stage II colorectal cancer patients more accurately than clinical factors.Oncologist. 2015 Feb;20(2):127-33. doi: 10.1634/theoncologist.2014-0325. Epub 2015 Jan 5. Oncologist. 2015. PMID: 25561511 Free PMC article.
-
MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside.World J Gastroenterol. 2018 Jul 21;24(27):2949-2973. doi: 10.3748/wjg.v24.i27.2949. World J Gastroenterol. 2018. PMID: 30038463 Free PMC article. Review.
Cited by
-
Assessment of Nuclear ZEB2 as a Biomarker for Colorectal Cancer Outcome and TNM Risk Stratification.JAMA Netw Open. 2018 Oct 5;1(6):e183115. doi: 10.1001/jamanetworkopen.2018.3115. JAMA Netw Open. 2018. PMID: 30646224 Free PMC article.
-
Evolving notions on immune response in colorectal cancer and their implications for biomarker development.Inflamm Res. 2018 May;67(5):375-389. doi: 10.1007/s00011-017-1128-1. Epub 2018 Jan 10. Inflamm Res. 2018. PMID: 29322204 Review.
-
Lymphovascular invasion is a high risk factor for stage I/II colorectal cancer: a systematic review and meta-analysis.Oncotarget. 2017 Jul 11;8(28):46565-46579. doi: 10.18632/oncotarget.15425. Oncotarget. 2017. PMID: 28430621 Free PMC article. Review.
-
A comparative analysis and guidance for individualized chemotherapy of stage II and III colorectal cancer patients based on pathological markers.Sci Rep. 2016 Nov 15;6:37240. doi: 10.1038/srep37240. Sci Rep. 2016. PMID: 27845412 Free PMC article. Clinical Trial.
-
Machine learning-based integration develops an immune-derived lncRNA signature for improving outcomes in colorectal cancer.Nat Commun. 2022 Feb 10;13(1):816. doi: 10.1038/s41467-022-28421-6. Nat Commun. 2022. PMID: 35145098 Free PMC article.
References
-
- Horner MJRL, Krapcho M, Neyman N, et al. SEER Cancer Statistics Review, 1975-2006. National Cancer Institute; 2009. FS2.
-
- Cancer in California . Department of Health Services; State of California: Dec, 2005. 1988-2002. 2005.[FS3]
-
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49. - PubMed
-
- Quasar Collaborative G. Gray R, Barnwell J, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370:2020–9. [FS4][FS5] - PubMed
-
- Compton CC, Fielding LP, Burgart LJ, et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000;124:979–94. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical